Response of experimental retinal neovascularization to thiazolidinediones

Toshinori Murata, Yasuaki Hata, Tatsuro Ishibashi, Sarah Kim, Willa A. Hsueh, Ronald E. Law, David R. Hinton

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Objective: To determine the effect of thiazolidinediones (TZDs) on experimental retinal neovascularization. Methods: The ability of the TZDs troglitazone and rosiglitazone maleate (1-20 μmol/L) to inhibit retinal endothelial cell (REC) proliferation, migration, tube formation, and signaling was determined in response to vascular endothelial growth factor (VEGF). In vivo studies were performed using the oxygen-induced ischemia model of retinal neovascularization. Neonatal mice were treated with intravitreous injection of 0.5 μL of troglitazone (100 μmol/L) or rosiglitazone maleate (100 μmol/L), or vehicle, and retinal neovascularization was assayed qualitatively and quantitatively by means of angiography and histological examination. Results: Expression of the TZD receptor, pemxisome proliferator-activated receptor γ, was confirmed in RECs by means of Western immunoblotting. Rosiglitazone and troglitazone inhibited VEGF-induced migration (P<.05), proliferation (P<.05), and tube formation (P<.01) by RECs in vitro beginning at 10 μmol/L. Rosiglitazone and troglitazone inhibited phosphorylation of extracellular signal-regulated mitogen-activated protein kinase 1 in RECs. Intravitreous injection of rosiglitazone or troglitazone inhibited development of retinal neovascularization (P<.01) but did not significantly inhibit VEGF overexpression in the ganglion cell layer of the ischemic retina. Conclusion: The TZDs inhibit experimental retinal neovascularization with an effect that is primarily downstream of VEGF expression. Clinical Relevance: The TZDs are widely prescribed and should be evaluated for their potential to inhibit the progression of diabetic retinopathy.

Original languageEnglish
Pages (from-to)709-717
Number of pages9
JournalArchives of Ophthalmology
Volume119
Issue number5
DOIs
Publication statusPublished - Jan 1 2001

Fingerprint

rosiglitazone
troglitazone
Retinal Neovascularization
Thiazolidinediones
Vascular Endothelial Growth Factor A
Injections
PPAR gamma
Mitogen-Activated Protein Kinase 1
Diabetic Retinopathy
Ganglia
Cell Movement
Retina
Angiography
Ischemia
Endothelial Cells
Western Blotting
Phosphorylation
Cell Proliferation
Oxygen

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Response of experimental retinal neovascularization to thiazolidinediones. / Murata, Toshinori; Hata, Yasuaki; Ishibashi, Tatsuro; Kim, Sarah; Hsueh, Willa A.; Law, Ronald E.; Hinton, David R.

In: Archives of Ophthalmology, Vol. 119, No. 5, 01.01.2001, p. 709-717.

Research output: Contribution to journalArticle

Murata, Toshinori ; Hata, Yasuaki ; Ishibashi, Tatsuro ; Kim, Sarah ; Hsueh, Willa A. ; Law, Ronald E. ; Hinton, David R. / Response of experimental retinal neovascularization to thiazolidinediones. In: Archives of Ophthalmology. 2001 ; Vol. 119, No. 5. pp. 709-717.
@article{6f9ef71bc7b44f6ba30e5af3dbb22216,
title = "Response of experimental retinal neovascularization to thiazolidinediones",
abstract = "Objective: To determine the effect of thiazolidinediones (TZDs) on experimental retinal neovascularization. Methods: The ability of the TZDs troglitazone and rosiglitazone maleate (1-20 μmol/L) to inhibit retinal endothelial cell (REC) proliferation, migration, tube formation, and signaling was determined in response to vascular endothelial growth factor (VEGF). In vivo studies were performed using the oxygen-induced ischemia model of retinal neovascularization. Neonatal mice were treated with intravitreous injection of 0.5 μL of troglitazone (100 μmol/L) or rosiglitazone maleate (100 μmol/L), or vehicle, and retinal neovascularization was assayed qualitatively and quantitatively by means of angiography and histological examination. Results: Expression of the TZD receptor, pemxisome proliferator-activated receptor γ, was confirmed in RECs by means of Western immunoblotting. Rosiglitazone and troglitazone inhibited VEGF-induced migration (P<.05), proliferation (P<.05), and tube formation (P<.01) by RECs in vitro beginning at 10 μmol/L. Rosiglitazone and troglitazone inhibited phosphorylation of extracellular signal-regulated mitogen-activated protein kinase 1 in RECs. Intravitreous injection of rosiglitazone or troglitazone inhibited development of retinal neovascularization (P<.01) but did not significantly inhibit VEGF overexpression in the ganglion cell layer of the ischemic retina. Conclusion: The TZDs inhibit experimental retinal neovascularization with an effect that is primarily downstream of VEGF expression. Clinical Relevance: The TZDs are widely prescribed and should be evaluated for their potential to inhibit the progression of diabetic retinopathy.",
author = "Toshinori Murata and Yasuaki Hata and Tatsuro Ishibashi and Sarah Kim and Hsueh, {Willa A.} and Law, {Ronald E.} and Hinton, {David R.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1001/archopht.119.5.709",
language = "English",
volume = "119",
pages = "709--717",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Response of experimental retinal neovascularization to thiazolidinediones

AU - Murata, Toshinori

AU - Hata, Yasuaki

AU - Ishibashi, Tatsuro

AU - Kim, Sarah

AU - Hsueh, Willa A.

AU - Law, Ronald E.

AU - Hinton, David R.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Objective: To determine the effect of thiazolidinediones (TZDs) on experimental retinal neovascularization. Methods: The ability of the TZDs troglitazone and rosiglitazone maleate (1-20 μmol/L) to inhibit retinal endothelial cell (REC) proliferation, migration, tube formation, and signaling was determined in response to vascular endothelial growth factor (VEGF). In vivo studies were performed using the oxygen-induced ischemia model of retinal neovascularization. Neonatal mice were treated with intravitreous injection of 0.5 μL of troglitazone (100 μmol/L) or rosiglitazone maleate (100 μmol/L), or vehicle, and retinal neovascularization was assayed qualitatively and quantitatively by means of angiography and histological examination. Results: Expression of the TZD receptor, pemxisome proliferator-activated receptor γ, was confirmed in RECs by means of Western immunoblotting. Rosiglitazone and troglitazone inhibited VEGF-induced migration (P<.05), proliferation (P<.05), and tube formation (P<.01) by RECs in vitro beginning at 10 μmol/L. Rosiglitazone and troglitazone inhibited phosphorylation of extracellular signal-regulated mitogen-activated protein kinase 1 in RECs. Intravitreous injection of rosiglitazone or troglitazone inhibited development of retinal neovascularization (P<.01) but did not significantly inhibit VEGF overexpression in the ganglion cell layer of the ischemic retina. Conclusion: The TZDs inhibit experimental retinal neovascularization with an effect that is primarily downstream of VEGF expression. Clinical Relevance: The TZDs are widely prescribed and should be evaluated for their potential to inhibit the progression of diabetic retinopathy.

AB - Objective: To determine the effect of thiazolidinediones (TZDs) on experimental retinal neovascularization. Methods: The ability of the TZDs troglitazone and rosiglitazone maleate (1-20 μmol/L) to inhibit retinal endothelial cell (REC) proliferation, migration, tube formation, and signaling was determined in response to vascular endothelial growth factor (VEGF). In vivo studies were performed using the oxygen-induced ischemia model of retinal neovascularization. Neonatal mice were treated with intravitreous injection of 0.5 μL of troglitazone (100 μmol/L) or rosiglitazone maleate (100 μmol/L), or vehicle, and retinal neovascularization was assayed qualitatively and quantitatively by means of angiography and histological examination. Results: Expression of the TZD receptor, pemxisome proliferator-activated receptor γ, was confirmed in RECs by means of Western immunoblotting. Rosiglitazone and troglitazone inhibited VEGF-induced migration (P<.05), proliferation (P<.05), and tube formation (P<.01) by RECs in vitro beginning at 10 μmol/L. Rosiglitazone and troglitazone inhibited phosphorylation of extracellular signal-regulated mitogen-activated protein kinase 1 in RECs. Intravitreous injection of rosiglitazone or troglitazone inhibited development of retinal neovascularization (P<.01) but did not significantly inhibit VEGF overexpression in the ganglion cell layer of the ischemic retina. Conclusion: The TZDs inhibit experimental retinal neovascularization with an effect that is primarily downstream of VEGF expression. Clinical Relevance: The TZDs are widely prescribed and should be evaluated for their potential to inhibit the progression of diabetic retinopathy.

UR - http://www.scopus.com/inward/record.url?scp=0035013061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035013061&partnerID=8YFLogxK

U2 - 10.1001/archopht.119.5.709

DO - 10.1001/archopht.119.5.709

M3 - Article

C2 - 11346398

AN - SCOPUS:0035013061

VL - 119

SP - 709

EP - 717

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 5

ER -